Vor Biopharma Inc. (NASDAQ:VOR - Get Free Report)'s share price rose 4.8% during mid-day trading on Friday. The stock traded as high as $19.15 and last traded at $19.4040. Approximately 113,136 shares traded hands during mid-day trading, a decline of 89% from the average daily volume of 1,019,825 shares. The stock had previously closed at $18.52.
Analysts Set New Price Targets
VOR has been the topic of a number of recent research reports. Wedbush boosted their target price on shares of Vor Biopharma from $18.00 to $27.00 and gave the stock a "neutral" rating in a research report on Wednesday, August 12th. William Blair initiated coverage on Vor Biopharma in a research note on Wednesday, October 21st. They set an "outperform" rating for the company. Wall Street Zen cut Vor Biopharma from a "hold" rating to a "sell" rating in a research report on Saturday, October 31st. Citigroup upgraded shares of Vor Biopharma to a "strong-buy" rating in a research report on Thursday, October 15th. Finally, Stifel Nicolaus set a $40.00 price target on shares of Vor Biopharma in a report on Monday, November 2nd. Two investment analysts have rated the stock with a Strong Buy rating, five have issued a Buy rating and two have given a Hold rating to the company's stock. According to MarketBeat.com, the company has a consensus rating of "Buy" and an average target price of $38.29.
View Our Latest Report on Vor Biopharma
Vor Biopharma Stock Up 6.1%
The company has a fifty day moving average of $19.55 and a two-hundred day moving average of $17.63.
Vor Biopharma (NASDAQ:VOR - Get Free Report) last issued its quarterly earnings results on Friday, October 30th. The company reported ($1.45) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.81) by ($0.64). Analysts predict that Vor Biopharma Inc. will post -2.74 earnings per share for the current year.
Institutional Trading of Vor Biopharma
Hedge funds have recently modified their holdings of the stock. Bank of America Corp DE boosted its stake in shares of Vor Biopharma by 28,408.1% in the 1st quarter. Bank of America Corp DE now owns 112,892 shares of the company's stock valued at $2,014,000 after purchasing an additional 112,496 shares during the last quarter. Renaissance Technologies LLC bought a new position in Vor Biopharma during the first quarter worth about $2,298,000. Braidwell LP increased its holdings in shares of Vor Biopharma by 22.8% in the second quarter. Braidwell LP now owns 573,104 shares of the company's stock worth $10,551,000 after acquiring an additional 106,330 shares in the last quarter. Wellington Management Group LLP bought a new position in Vor Biopharma during the 2nd quarter worth about $499,000. Finally, Bank of New York Mellon Corp bought a new position in Vor Biopharma in the second quarter valued at $1,799,000. 97.29% of the stock is owned by institutional investors.
About Vor Biopharma
(
Get Free Report)
Vor Biopharma is a clinical-stage biotechnology company focused on developing cell therapies for blood cancers. The company combines gene editing of blood stem cells with engineered immune-cell therapies, with the goal of enabling targeted treatment while protecting healthy blood-forming cells. Its research has included trem-cel, an investigational gene-edited stem cell therapy designed to remove the CD33 protein from transplanted cells, and VCAR33, an investigational CAR T-cell therapy targeting CD33.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Vor Biopharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Vor Biopharma wasn't on the list.
While Vor Biopharma currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.